Compare SUPN & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUPN | PBH |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2010 | 2004 |
| Metric | SUPN | PBH |
|---|---|---|
| Price | $37.86 | $50.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $60.50 | ★ $67.80 |
| AVG Volume (30 Days) | ★ 627.8K | 548.8K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | $392,755,000.00 | ★ $975,777,000.00 |
| Revenue This Year | $22.95 | $17.03 |
| Revenue Next Year | $54.39 | $6.06 |
| P/E Ratio | ★ N/A | $80.70 |
| Revenue Growth | N/A | ★ 36.77 |
| 52 Week Low | $39.36 | $42.62 |
| 52 Week High | $59.68 | $71.07 |
| Indicator | SUPN | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 27.30 | 60.51 |
| Support Level | N/A | $49.73 |
| Resistance Level | $52.33 | $51.57 |
| Average True Range (ATR) | 1.58 | 1.22 |
| MACD | -0.38 | 0.52 |
| Stochastic Oscillator | 6.09 | 85.48 |
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.